Clinical trials located in

Löwenstein

Löwenstein city is located in Germany. Currently, 9 clinical trials are being conducted in this city.

Löwenstein, nestled in the scenic Swabian-Franconian Forest in Germany, is a city steeped in history and natural beauty. Founded in the 12th century, it was named after the castle Löwenstein. The city offers a glimpse into medieval times with its well-preserved architecture and ancient ruins. Löwenstein’s elevation provides breathtaking views of the surrounding countryside, making it a unique blend of historical charm and natural wonder. The city is also known for its vineyards, contributing to the region’s rich wine culture.

  • CT-EU-00029633

    Ceralasertib & durvalumab vs docetaxel in advanced lung cancer study

    This is an open-label study titled LATIFY, which means everyone will know the type of treatment they are receiving. The study team is looking into a specific type of lung cancer, called Non-Small Cell Lung Cancer (NSCLC) which did not get better after previous treatments. Two treatments will be tested, a new combination of ceralasertib plus durvalumab, compared to a commonly used treatment, docetaxel. Doctors will track participants’ health over time to see which treatment helps people live longer. Understanding the results will help doctors responsibly give the best treatment for patients with this type of lung cancer.

    • Ceralasertib
    • Durvalumab
    • Docetaxel
  • Evaluating durvalumab in small cell lung cancer treatment

    This study examines the effectiveness and safety of adding durvalumab to standard radiochemotherapy for patients with limited-stage small cell lung cancer (SCLC). It’s an open-label trial where patients are randomly divided into two groups. One group receives durvalumab in combination with standard therapy, while the other receives only standard therapy. The primary goal is to assess how well the combination therapy works in preventing cancer progression, with a focus on patient survival and response to treatment.

    • Durvalumab
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Evaluating treatment strategies for small-cell lung cancer: A clinical trial with lurbinectedin, irinotecan, and topotecan

    This is a large test the researchers are running to help people with a certain type of lung cancer (called Small-cell Lung Cancer) that’s come back after they’ve had one type of treatment that contains platinum. The researchers are using three different ways of giving medicine to see which is best. The first way is to give only lurbinectedin. The second way is to give lurbinectedin and irinotecan together. The third way is to let the doctor decide to use topotecan or irinotecan alone. People’s selection to these groups will be by chance.

    • Irinotecan
    • topotecan
    • Lurbinectedin
  • Study of savolitinib and osimertinib Vs chemotherapy in advancing lung cancer

    This clinical trial will include approximately 324 people with a specific type of advanced lung cancer that has not improved with a specific treatment, osimertinib. People in this study will receive a combination of two drugs, savolitinib and osimertinib, or standard chemotherapy. The aim is to find out which treatment is more effective and safe. A person’s cancer will be monitored to see how it responds to treatment. If the cancer gets worse or the side effects become too much to bear, the person may stop participating in the study. The study will measure responses such as the number of people who see improvement in their cancer treatment, the time it takes for symptoms to get worse and the presence of drugs in the body.

    • savolitinib
    • Osimertinib
    • Pemetrexed
    • Cisplatin
    • Carboplatin
  • Study of the effects of Durvalumab and Domvanalimab on non-small cell lung cancer

    This study looks at two drugs – Durvalumab and Domvanalimab – and how they may help people with a type of lung cancer that cannot be removed by surgery. These medicines are given to patients after special treatment combining chemotherapy and radiotherapy. The goal is to find out whether these drugs provide benefits and are safe to use. During the trial, patients will be given the real drug or a placebo (a substance that has no therapeutic effect), without knowing which one they will receive. The study will measure how long it takes for the disease to worsen, how long people live and how many people respond positively to treatment. This clinical trial is testing the effectiveness of Durvalumab and Domvanalimab – two drugs – in the treatment of stage III lung cancer that cannot be surgically removed. After undergoing chemotherapy and radiation therapy, participants will be given these drugs to assess their safety. The study is double-blind, meaning neither participants nor researchers know who is receiving the actual drug and who is receiving the placebo. The study will monitor whether the cancer gets worse and what the rate of positive reactions to the drugs is. A study is being conducted with two drugs, Durvalumab and Domvanalimab, for patients with advanced forms of lung cancer that cannot be treated with surgery. After undergoing combined chemotherapy and radiation therapy, participants receive these drugs. The study was designed so that neither the patient nor the doctor knew whether the correct drug or a placebo was being administered. The time until the disease worsens, how long participants live and the number of patients who see improvement with the drugs will be measured.

    • Domvanalimab
    • Durvalumab
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in Germany:

.